Navigating the New Patent Regime for Pharmaceuticals

Feb. 26, 2018
Toronto Online

OBA Information Technology & Intellectual Property LAW PROGRAM | 12:30 PM to 2:00 PM

In September 2017, the Canadian government made substantial changes to the Patented Medicines (Notice of Compliance) Regulations (PM(NOC)), governing pharmaceutical patent litigation, as required under the Canada-European Union Comprehensive Economic and Trade Agreement (CETA).  Join us to explore the implications of these amendments for both innovative and generic pharmaceutical companies, including:

  • The change from an application-based proceeding to an action-based proceeding
  • New early disclosure requirements
  • Expansion of section 8 damages, and other new remedies
  • Shifting of the burden of proof


Get up to speed on what these changes mean for your practice, and gather valuable insights on the best process for timely resolution of PM(NOC) litigation under this new regime.

PROGRAM SPEAKERS

Keith Aguilera, Legal Counsel, GSK Canada
Carol Hitchman, Counsel, Sprigings Intellectual Property Law
Jordan Scopa, Partner, Goodmans LLP
Kristin Wall, Partner, Norton Rose Fulbright Canada LLP

PROGRAM CHAIR

Daniel Daniele, Norton Rose Fulbright Canada LLP

PROGRAM DETAILS

Date: Monday, February 26, 2018
Time: 12:30 pm - 2:00 pm Program
 

PROGRAM PRICE

CBA Member: $65* | CBA Student Member: $35* | Non-Member: $105*

*plus applicable taxes

 

printPrint     Bookmark and Share

    OTHER FORMATS AVAILABLE

    This program is also available In Person
     

    Viewer Specifications for Webcast

    Adobe Acrobat Reader 10.0+
    High-speed internet connectionTest
    Modern web browser, e.g. Internet Explorer 11+

 

CONTACT INFO

Ontario Bar Association
Tele: (416) 869-1047
Toll-free in Ontario
1-800-668-8900
E-Mail: registrations@oba.org
Web: www.oba.org